4.5 Article

Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis

Publisher

SPRINGER
DOI: 10.1007/s10096-021-04378-0

Keywords

Community-acquired pneumonia; Severe pneumonia; Ceftaroline; Pneumonia; Antimicrobials

Funding

  1. CRUE-CSIC agreement
  2. Springer Nature
  3. Pfizer [Aspire: INSPIIRE WI244153]
  4. CIBER de Enfermedades Respiratorias [CIBERES CB06/06/0028]
  5. 2009 Support to Research Groups of Catalonia 911, IDIBAPS
  6. Pfizer (Aspire)
  7. SEPAR fellowship 2018
  8. Fondo de Investigacion Sanitaria [PI19/00207]

Ask authors/readers for more resources

The study found that empirically using ceftaroline in hospitalized patients with severe CAP is associated with a decreased risk of in-hospital mortality.
The purpose of this study is to evaluate the in-hospital mortality of community-acquired pneumonia (CAP) treated with ceftaroline in comparison with standard therapy. This was a retrospective observational study in two centers. Hospitalized patients with CAP were grouped according to the empiric regimen (ceftaroline versus standard therapy) and analyzed using a propensity score matching (PSM) method to reduce confounding factors. Out of the 6981 patients enrolled, 5640 met the inclusion criteria, and 89 of these received ceftaroline. After PSM, 78 patients were considered in the ceftaroline group (cases) and 78 in the standard group (controls). Ceftaroline was mainly prescribed in cases with severe pneumonia (67% vs. 56%, p = 0.215) with high suspicion of Staphylococcus aureus infection (9% vs. 0%, p = 0.026). Cases had a longer length of hospital stay (13 days vs. 10 days, p = 0.007), while an increased risk of in-hospital mortality was observed in the control group compared to the case group (13% vs. 21%, HR 0.41; 95% CI 0.18 to 0.62, p = 0.003). The empiric use of ceftaroline in hospitalized patients with severe CAP was associated with a decreased risk of in-hospital mortality.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available